Detailed description of which three groups of people are not suitable for taking Nintedanib

Nintedanib (Nintedanib) is a multi-target tyrosine kinase inhibitor mainly used to treat idiopathic pulmonary fibrosis (IPF) and certain types of non-small cell lung cancer (NSCLC). Although it has shown good clinical efficacy, not all patients are suitable for taking this drug. The following details the three categories of people who are not suitable for taking nintedanib and their reasons.

Patients with severely impaired liver function should not take nintedanib. Nintedanib is mainly metabolized by the liver. Hepatic insufficiency will cause the drug to accumulate in the body, increasing the risk of toxic side effects. Especially for patients with liver function Child-Pugh B and above, their drug clearance ability is significantly reduced, which can easily cause severe liver damage or drug-related adverse reactions. Therefore, doctors generally recommend that such patients avoid the use of nintedanib or use it with caution after careful monitoring and weighing the risks and benefits.

Pregnant and breastfeeding women should avoid taking nintedanib. Animal experiments show that nintedanib may cause teratogenic effects on the fetus and has potential risks of reproductive toxicity. There is currently insufficient clinical data to prove its safety during pregnancy, so the use of this drug by pregnant women may have serious effects on fetal health. In addition, it is not clear whether nintedanib is excreted through breast milk. To prevent the baby from being exposed to the drug, breastfeeding women should also avoid taking it or suspend breastfeeding.

Patients with active bleeding or a high risk of bleeding are not candidates for nintedanib. As a tyrosine kinase inhibitor, nintedanib has anti-angiogenic effects, which may affect vascular repair and coagulation function and increase the risk of bleeding events. Especially for patients with a history of peptic ulcers, cerebral hemorrhage, or who are taking anticoagulants, taking nintedanib may aggravate bleeding tendencies and lead to serious complications. Therefore, such patients need to comprehensively assess the risk of bleeding before taking the drug, and doctors will decide whether to disable or take strict monitoring measures after weighing the pros and cons.

In summary, patients with severely impaired liver function, pregnant and lactating women, and patients with active bleeding or high risk of bleeding are the main contraindications for nintedanib. Properly identifying and avoiding these high-risk groups can effectively reduce the occurrence of adverse drug reactions and ensure safe medication use for patients. During the clinical medication process, doctors should conduct a comprehensive assessment based on the patient's specific situation, and instruct patients on correct use and regular review.

Reference materials:https://www.drugs.com/